Bioproduction bottles are single-use flexible containers used for critical liquid-handling applications in the biopharmaceutical industry. These bottles are alternatives to traditional stainless steel systems. Their demand has soared in research & development activities to prevent cross-contamination of materials. Moreover, the evolution of tissue engineering or cell & gene therapy in recent years has also surged their usage in clinical testing laboratories worldwide.
The Global Bioproduction Bottles Market is projected to grow at a CAGR of around 19.29% during the forecast period, i.e., 2022-27. The global biopharmaceutical industry continues to grow at a steady pace on account of rising investments in research & development for improving global health. In order to treat diseases, the research-based biopharmaceutical sector has played a vital role in the development of new medicines and vaccines. As a result, numerous R&D activities and the establishment of new biopharmaceutical manufacturing facilities in countries like the US, Canada, China, Russia, etc., have positively influenced the demand for bioproduction bottles during 2017-19.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: USA, Canada, Mexico|
|South America: Brazil, and Others|
|Europe: UK, Germany, France, Spain, Italy and Others|
|Asia-Pacific: China, India, Japan, South Korea, Australia and Others|
|Middle East & Africa: GCC, Africa and Others|
|Key Companies Profiled||Thermo Fisher Scientific, Gerresheimer Glas GmbH, Essco Glass, Spectrum Chemical Manufacturing Corporation, Corning, SGD Pharma, Duran Group, Beatson Clark, Foxx Life Sciences and Others|
|Unit Denominations||USD Million/Billion|
Furthermore, with the Covid-19 pandemic in 2020, biopharmaceutical companies got involved in various R&D activities for developing potential treatments, diagnostics, & vaccines for the patients. It, in turn, surged the demand for bioproduction bottles for the R&D conducted. As of February 2021, around 1,000 clinical trials were conducted just for developing Covid-19 treatment & vaccines. Nevertheless, several clinical trials & product launches got suspended other than those for Covid-19. However, faster approvals by WHO for large-scale production of several vaccines helped compensate for the overall impact on the sales of bioproduction bottles. It, in turn, catalyzed the manufacturing of vaccines globally and subsequently surpassed the overall demand for bioproduction bottles in the later part of 2020.
Notably, the rising production & approvals of Covid-19 vaccines worldwide would continue fostering the demand for bioproduction bottles in the forecast years, too. In line with the growing demand for vaccines, several bottle & glass manufacturers like DWK Life Sciences, etc., have stated that they would raise their bottle production capacity to almost double in 2022.
Impact of Covid-19 on Global Bioproduction Bottles Market
In 2020, the Covid-19 pandemic brought significant challenges to the Global Bioproduction Bottles Market, primarily by impacting the supply of drugs & APIs (Active Pharmaceutical Ingredients), along with the biopharmaceutical packaging industry. In May 2020, practitioners raised apprehension toward the availability of primary parenteral packaging consumables, including bottles, vials, containers, syringes, stoppers, etc., for the packaging of drugs & vaccines to be traded globally. Several clinical trials & processes were on hold owing to the global crisis, which, in turn, severely impacted the biologics & biosimilars development.
The number of clinical pharmaceuticals, biotech, & research organizations, viz., Eli Lilly, Pfizer, Bristol-Myers Squibb, Addex Therapeutics, Provention Bio, and contract research organizations IQVIA and Icon announced the postponement of the clinical trials carried out in their laboratories. Therefore, it became difficult for many manufacturers to provide bottles, blister packagings, pre-fillable syringes, vials, and ampoules to biopharmaceutical companies. However, the increased focus of different countries worldwide toward developing Covid-19 vaccines surged the demand for bioproduction bottles amidst the crisis.
In 2020, clinicaltrials.gov discovered that around 1,099 trials got postponed due to the pandemic. As per surveys in the US & Europe, nearly 200 oncology trials were operative from 17th March till 3rd April 2020. However, owing to the pandemic, a delay of around 6-8 months in clinical research was observed, which negatively impacted the market of bioproduction bottles since they are used for drug storage. The pandemic caused significant losses & interruption in the production facilities to various industries globally. However, it also created interest & cognizance in the biopharmaceutical sector by devising investment opportunities for developing biologics & vaccines for the Covid-19 treatment.
When WHO declared the Covid-19 outbreak a pandemic, several biopharmaceutical & biotech companies and clinical research organizations got engaged in developing Covid-19 treatments & vaccines. In addition, the growing demand for biological products and the evolving cell and gene therapies also boosted the demand for biopharma bottles. Moreover, several mergers, acquisitions, partnerships, & collaborations took place for developing the Covid-19 vaccines. For instance:
Key Trend in the Global Bioproduction Bottles Market
Historically, Biologics became a vital medicine for the treatment of chronic diseases, such as diabetes, autoimmune disorders, and cancers. However, their high price tags encouraged the development of another low-cost option, i.e., Biosimilars, which incur low development costs & time. Moreover, the evolution of the regulatory framework in countries like the US, China, & Japan has provided significant opportunities for the adoption of Biosimilars. Several regulatory bodies that actively regulate the development & commercialization of biosimilars include European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and the World Health Organization (WHO). By May 2020, Europe approved around 60 biosimilars. Some of the approved biosimilars in the EU include Adalimumab, Bevacizumab, Epoetin alfa, Etanercept, etc.
The key aim of developing biosimilars was access to the drug for a specific treatment to all. Hence, the growing worldwide inclination toward manufacturing biosimilars would drive the Bioproduction Bottles Market during 2022-27. For instance:
By Material Type:
Of them all, plastic bioproduction bottles held a considerable share in the Global Bioproduction Bottles Market during 2017-2020, owing to their features like lightweight, robustness, resistance from inorganic chemicals, & their availability in different sizes. On the other hand, glass bioproduction bottles are fragile and can release alkalis to aqueous preparations. Plastic is preferred extensively for many solutions since it does not display a pH change over time, whereas glass containers do. However, the selection of plastic & glass bottles majorly varies on the application areas & requirements. The low cost of glass bottles enables them to be a feasible option for the R&D activities of biopharmaceutical companies.
Moreover, the usage of single-use technology in plastic bioproduction bottles is also one of the crucial factors positively impacting their demand since this technology develops the upstream & downstream processes with more safety, sterility, and reliability. The changing landscape of biopharmaceuticals has triggered many opportunities for new technological integrations. Moreover, with more biologics going off-patent and new treatments are being introduced, there has been a diversification of the drug pipeline, with companies focusing on developing drugs at lower costs. Hence, the usage of single-use technology in biopharmaceuticals is quite instrumental in positively impacting the demand for plastic bioproduction bottles.
By Capacity Type:
Here, bioproduction bottles with a capacity of up to 30 ml dominated the market in 2021 due to their extensive usage for testing & storage purposes in both clinical & commercial applications. At the clinical stage, bottles with up to 30ml capacity are the most preferred ones to undergo any test or experiment. Moreover, commercially, the packaging of single-dose vaccines deploys these bottles substantially. Further, the Covid-19 pandemic has also played a crucial role in catalyzing their demand across academia, contract research organizations, & pharmaceutical industries, and the same trend is likely to be followed during the forecast period.
By Development Phase:
With the rapidly growing incidences of chronic diseases like cancer, diabetes, etc., worldwide, the utilization of biologics & biosimilars for their cure is registering an uptrend. Many developed countries shifted toward biopharmaceutical manufacturing during 2017-19, which has positively influenced the demand for bioproduction bottles.
Furthermore, the commercial segment experienced robust growth after the Covid-19 pandemic in 2020 since various biopharmaceutical companies actively started focusing on developing vaccines. Most companies received vaccine approval at the end of 2020 & the beginning of 2021. The surging number of vaccine approvals led to their commercialization, which, in turn, positively impacted the demand for bioproduction bottles.
According to the International Federation of Pharmaceutical Manufacturers Association, 12 billion vaccines were expected to be produced by the end of 2021. Moreover, the rising partnerships among biopharmaceutical companies to accelerate the Covid-19 vaccine manufacturing are other crucial aspects projected to strongly contribute to the overall market growth in the forthcoming period.
By Molecule Type:
Of all Molecule Types, Proteins have registered the highest growing demand. It owes to Monoclonal antibodies (mAbs) utilized to provide therapeutic solutions for immune-oncology & immunotherapy. Hence, the ability of monoclonal antibodies to fight against harmful pathogens like viruses has increased their usage for the treatment of pediatric patients suffering from Covid-19. For instance:
The demand for bioproduction bottles for Gene therapy is expected to register an exponential growth during 2022-27 due to the development of regenerative medicine worldwide. The rapidly growing regenerative medicine industry attributes primarily to the increasing number of patients diagnosed with chronic diseases, such as diabetes, Alzheimer's, cancer, renal failure, spinal cord injury, etc. Technological advancements in stem cell therapies have led to the mounting demand for the treatment of cancer & diabetes patients globally.
Geographically, the Global Bioproduction Bottles Market expands across:
Of all regions globally, North America captured the highest market share in the Bioproduction Bottles Market during 2017-20, owing to the extensive presence of several biopharmaceutical manufacturing facilities across the region and the significant research & development for the introduction of new treatments.
Furthermore, the Covid-19 pandemic in 2020 encouraged the governments to introduce robust plans to boost biopharmaceutical manufacturing in the countries. Hence, the launch of new manufacturing facilities provided new opportunities to the leading manufacturers of bioproduction bottles across the region, which, in turn, has strongly contributed to the regional market growth. For instance:
Furthermore, across North America, the bioproduction market in the US is anticipated to touch USD 600 million by 2027. The United States, home to the largest number of biopharmaceutical manufacturing companies, such as Pfizer, Johnson & Johnson, Merck & Co., holds the highest market share in the region. Continuous developments by biopharmaceutical companies for the treatment of several chronic diseases have been a major contributor to the demand for bioproduction bottles across the country.
The burgeoning demand for better treatment among patients, the boost in the development of personalized medicines, and increasing incidences of chronic diseases have led to higher investments in cell & gene therapies.
Key Driver: Rapid Development of Vaccines to Induce Demand for Bioproduction Bottles
The growth of the Global Bioproduction Bottles Market attributes primarily to the growing research & development on vaccines worldwide & their commercialization, coupled with biopharmaceutical companies worldwide planning to expand their production capacities.
Furthermore, the Covid-19 pandemic in 2020 increased the focus of various governments worldwide to develop local biopharmaceutical sectors across different countries. Besides, the biopharmaceutical companies initiated the development & manufacturing of Covid-19 vaccines around the US, the UK, Canada, etc. Hence, this has further positively impacted the growth of the Global Bioproduction Bottles Market.
Growth Challenge: Supply Chain Disruptions Associated with Bioproduction Bottles
The most prominent factor w.r.t to the Covid-19 vaccine manufacturing has been the availability of consumables. However, the sporadic availability of raw materials required for manufacturing consumables like bottles, single-use bags, tubing, sterile filters, tubes, stoppers, etc., significantly hampered the sales of bioproduction bottles in the first half of 2020. For instance:
Moreover, since organizations planned to change their product & service portfolio, there were shortages of biopharmaceutical equipment & supplies, viz., single-use bioprocessing technologies, bioreactors, analytical support, etc., even before the pandemic. It also hampered the Global Bioproduction Bottles Market to some extent.
Hence, the reduced production of Bioproduction bottles due to the global supply chain disruptions provided severe challenges to the market in the historical period, where the market would have performed well & experienced considerable growth.
Key Questions Answered in the Market Research Report:
Frequently Asked Questions
A. The Global Bioproduction Bottles Market is projected to grow at a CAGR of around 19.29% during 2022-27.
A. Storage & Sampling applications of bioproduction bottles are anticipated to present immense opportunities to the leading players in the Global Bioproduction Bottles Market during 2022-27.
A. Surging research & development activities in drug discovery & development to ensure proper storage & transportation of vaccines & pharmaceuticals under temperature-controlled conditions are the new white spaces for bioproduction bottles providers, which, in turn, would drive the Global Bioproduction Bottles Market through 2027.